OSE Immunotherapeutics (OSE.PA)

Executive Summary

OSE Immunotherapeutics is a clinical-stage French biotech developing first-in-class immunotherapies for cancer and autoimmune diseases. Its lead candidate, Tedopi® (OSE2101), is a T-cell epitope-based vaccine in a pivotal Phase 3 trial (ARTEMIA) for non-small cell lung cancer (NSCLC) in patients with prior checkpoint inhibitor failure. The company also advances OSE-127, a monoclonal antibody targeting CD127, which completed a Phase 2 trial in ulcerative colitis, and OSE-279, an anti-PD-1 antibody, in a Phase 1/2 study for solid tumors. With a diversified pipeline and a focus on neoantigen-based approaches, OSE is positioned to address high unmet needs in oncology and inflammation.

Upcoming Catalysts (preview)

• H2 2026Tedopi® Phase 3 NSCLC interim analysis40% success
• Q2 2026OSE-127 Phase 2 ulcerative colitis data readout60% success
• H1 2026OSE-279 Phase 1/2 initial efficacy and safety data55% success